Conservest Capital Advisors Inc. Buys 175 Shares of Amgen Inc. (NASDAQ:AMGN)

Conservest Capital Advisors Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 20.6% during the 4th quarter, Holdings Channel reports. The fund owned 1,026 shares of the medical research company’s stock after buying an additional 175 shares during the period. Conservest Capital Advisors Inc.’s holdings in Amgen were worth $267,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the third quarter valued at about $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the 3rd quarter valued at approximately $29,000. Centricity Wealth Management LLC acquired a new position in Amgen in the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC acquired a new position in Amgen in the 4th quarter worth approximately $36,000. Finally, Kennebec Savings Bank acquired a new position in Amgen in the 3rd quarter worth approximately $57,000. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by corporate insiders.

Amgen Trading Up 0.7 %

NASDAQ AMGN opened at $308.06 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a 50-day simple moving average of $280.87 and a 200-day simple moving average of $300.16. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market capitalization of $165.49 billion, a PE ratio of 40.80, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is currently 126.09%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on AMGN shares. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Finally, Citigroup restated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $314.09.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.